Atorvastatin Global Market Report 2024

Atorvastatin is a statin medication utilized to prevent cardiovascular disease in high-risk individuals and to manage abnormal lipid levels. It plays a crucial role in controlling high cholesterol and reducing the likelihood of cardiovascular diseases, thus serving as a fundamental component in both prevention and treatment of heart disease.

Atorvastatin is produced through two primary methods, chemical synthesis and biocatalysis. Biocatalysis is particularly important in the manufacturing process of atorvastatin, a drug aimed at lowering cholesterol levels. It is employed in diverse therapeutic applications, including cardiovascular disorders, obesity, inflammatory conditions, and others, utilized across various settings such as hospital pharmacies, retail pharmacies, and online pharmacies.

The atorvastatin market research report is one of a series of new reports that provides atorvastatin market statistics, including atorvastatin industry global market size, regional shares, competitors with an atorvastatin market share, detailed atorvastatin market segments, market trends, and opportunities, and any further data you may need to thrive in the atorvastatin industry. This atorvastatin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atorvastatin market size has grown rapidly in recent years. It will grow from $10.76 billion in 2023 to $11.86 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth observed in the historical period can be attributed to increased healthcare spending, rising rates of metabolic disorders and global obesity, sedentary lifestyles, unhealthy dietary practices in various populations, lack of physical activity, and a heightened focus on preventive healthcare and wellness worldwide.

The atorvastatin market size is expected to see rapid growth in the next few years. It will grow to $17.73 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to the increasing prevalence of cardiovascular diseases and high cholesterol levels, a growing elderly population more susceptible to heart conditions, rising awareness regarding cholesterol management and screening initiatives, and the availability of atorvastatin as a generic medication at competitive prices. Key trends anticipated during the forecast period include investments in research and development for innovative atorvastatin formulations, adoption of green chemistry in manufacturing processes, a shift towards personalized medicine and pharmacogenomics-based treatments, integration of digital health technologies, and the introduction of new atorvastatin formulations.

The atorvastatin market is poised for growth due to the increasing prevalence of cardiovascular diseases. Cardiovascular diseases encompass a variety of conditions affecting the heart and blood vessels. Factors contributing to their rising incidence include changes in lifestyle, demographic shifts, and environmental influences. Atorvastatin plays a crucial role in reducing the risk of major cardiovascular events such as heart attacks and strokes by addressing these factors. Its widespread adoption among patients with high cholesterol and other cardiovascular risk factors has significantly mitigated the overall burden of cardiovascular diseases. For example, in May 2023, the World Heart Federation reported an increase in cardiovascular disease-related deaths to 20.5 million in 2021. Hence, the expanding occurrence of cardiovascular diseases is fueling the growth of the atorvastatin market.

Leading firms in the atorvastatin market are concentrating on developing innovative products such as ready-made liquid oral suspensions to enhance the treatment of high cholesterol and associated cardiovascular risk factors. These formulations provide a convenient and effective means of administering medications, particularly beneficial for patients who have difficulty swallowing solid dosage forms. For instance, in June 2023, CMP Pharma, Inc., an American pharmaceutical company, introduced Atorvaliq (atorvastatin calcium) Oral Suspension, 20 mg/5 mL, approved by the US Food and Drug Administration (FDA). Atorvaliq caters specifically to patients needing atorvastatin but facing dysphagia or swallowing challenges. Its availability offers healthcare providers and eligible patients a safe, convenient, and FDA-approved liquid option.

In August 2023, Aspen Pharmacare Holdings Limited, a pharmaceutical company based in South Africa, acquired Viatris Inc.'s drug products Portfolio for $280 million. This acquisition was a strategic move by Aspen Pharmacare to expand its Portfolio by integrating Viatris's expertise in offering generic and specialty drugs for treating acute and chronic conditions. Viatris Inc., based in the US, provides various forms of pharmaceuticals including atorvastatin for different cardiovascular-related conditions.

Major companies operating in the atorvastatin market are Zydus Lifesciences, Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Pharmaceuticals Ltd., Apotex Pharmachem Inc., Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Centrient Pharmaceuticals, Accord Healthcare Ltd., Wockhardt Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Unichem Laboratories Ltd., Morepen, Ind-Swift Labs Ltd., Smilax Laboratories Limited, Saneca Pharmaceuticals AS, Combi-Blocks Inc., Shree HariKrishna Group, Srini Pharmaceuticals Pvt. Ltd., Suvan Lifesciences Ltd., Zenfold Sustainable Technologies.

North America was the largest region in the atorvastatin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atorvastatin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the atorvastatin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atorvastatin market consists of sales of atorvastatin calcium tablets, extended-release tablets, and generic tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.